Clinical Trials Browser

Phase 3 × Ureteral Neoplasms × Clear all

NCT03244384 2026-03-18

AMBASSADOR

Phase 3 Active not recruiting

Ureteral Neoplasms

NCT05092958 2026-03-18

Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study

Phase 3 Active not recruiting

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT06349668 2026-02-05

SMILe

Phase 3 Recruiting

Kidney Neoplasms, Ureteral Neoplasms, Vesico-Ureteral Reflux, Nephrolithiasis

NCT03474107 2026-01-09

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

Phase 3 Completed

608 enrolled 22 charts 1 FDA

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT00942331 2023-10-16

Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

Phase 3 Completed

506 enrolled 13 charts

Carcinoma, Transitional Cell, Prostatic Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT03296306 2017-09-28

FOCUS

Phase 3 Unknown

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT03193788 2017-06-21

PREMIER

Phase 3 Unknown

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms